Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07809334
Enrolling by invitation Observational

Implant Survival After Surgical Treatment of Peri-implantitis of Infra-bony Defects

NCT07809334 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2026-09-01
Last updated
2026-09-09

Condition(s) studied

Peri-implantitis

Investigational drug(s) / intervention(s)

Reconstructive therapy

Reconstructive therapy: Intervention: Following the elevation of a muco-periosteal flap, all granulation tissue was completely removed from the defect area, by means of titanium curettes and a titanium brush under irrigation. Consequently, implant surfaces were covered with EDTA 24% for 2 min and chlorhexidine 1% gel for 2 min. Thereafter, the infrabony defects were filled with a deproteinized bovine bone mineral with 10% collagen. All patients were asked to follow an individualized supportive care program.

Study summary

To report the 10 years outcomes of a reconstructive surgical protocol for peri-implantitis defects with different morphologies, by means of deproteinized bovine bone mineral with 10% collagen (DBBMC).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients rehabilitated with oral dental implants affected by peri-implantitis * A single peri-implantitis crater-like lesion with a Probing depth ofof ≥6 mm * No implant mobility, * Smokers Exclusion Criteria: * Probing depth \<6 mm; * Class II defects (characterized by consistent horizontal bone loss); * Multiple defects; * Implant mobility; * Subjects not interested in participating in the study;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
S.C. Chirurgia Maxillo-facciale U Torino Italy

More University of Turin, Italy trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07809334 on ClinicalTrials.gov ↗ ← All trials in Italy